Pelvital

Pelvital has developed and commercialized Flyte, a novel, prescription-only medical device for the non-surgical treatment of female stress urinary incontinence. The technology uses proprietary mechanotherapy—applying precise mechanical oscillations—to strengthen pelvic floor muscles through a 5-minute daily, 6-week at-home regimen. Backed by clinical data showing 82% continence rates, the company targets the massive, underserved market of women seeking alternatives to surgery or traditional pelvic floor exercises. Pelvital appears to be a private, commercial-stage company generating early revenue from direct-to-consumer and healthcare provider channels.

Proprietary mechanotherapy delivered via an intravaginal medical device that applies precise mechanical oscillations to strengthen pelvic floor muscles, integrated with sensor-based biofeedback and a digital app for guidance.

Flyte competes in the pelvic floor strengthening market against at-home biofeedback devices (e.g., Elvie Trainer, Perifit) and in-clinic physical therapy. Its key differentiation is its FDA-cleared status as a therapeutic device using proprietary mechanotherapy, positioning it as a more medically robust solution compared to consumer wellness products.